彭博制药业市场洞察会： 领航全球管线 —— 中国创新药的新估值 2026年3月10日（星期二）15:00 – 18:30 上海陆家嘴 2025年中国创新药以超过 1,360 亿美元的跨境交易额震撼全球，加速中国生物科技从"单点创 新"迈向"全球价值供给"，并在跨境合作与并购交易中展现出前所未有的影响力。步入2026年，当 中国管线成为驱动市场的核心动力源，我们正处于一个估值体系重塑的关键时刻。 本次 彭博制药业市场洞察会 为您深度梳理跨境授权与并购交易的最新趋势，在复盘ADC与肿瘤资 产出海逻辑的同时，前瞻 GLP-1 赛道在商业化路径上的激烈博弈。我们还将分享行业监管的最新 动态及其影响，并探讨人工智能在药物研发、管线效率、估值框架等方面有望造就的变革与赋 能。诚挚邀请您莅临上海，与生物医药行业领袖及彭博专家一起穿透波动把握关键信号，在变革 中共塑明智的全球化战略！ 活动议程 Cindy Wu 彭博行业研究(BI) 医药行业助理分析师 主讲嘉宾 主旨演讲：中国生物科技崛起 炉边对谈：从"翘首以盼"到"全球落地"的转折点 圆桌讨论：下一个"超级十亿美元"交易——未来并购技术路线重塑 互动交流 谢炘 中国生物制 ...

Core Insights - The article discusses the significant growth of China's innovative pharmaceuticals, projecting over $136 billion in cross-border transaction value by 2025, marking a shift from "single-point innovation" to "global value supply" [2] - The event aims to analyze the latest trends in cross-border licensing and M&A transactions, focusing on the ADC and oncology asset export logic, as well as the competitive landscape in the GLP-1 commercialization path [2] - The discussion will also cover the latest regulatory developments in the industry and the transformative potential of artificial intelligence in drug development, pipeline efficiency, and valuation frameworks [2] Event Details - The Bloomberg Pharmaceutical Market Insight Conference is scheduled for March 10, 2026, in Shanghai, featuring industry leaders and Bloomberg experts [2][3] - The agenda includes keynote speeches, panel discussions on future M&A technology routes, and interactive exchanges [3] Speakers - Notable speakers include executives from major companies such as China Biopharmaceutical Co., AbbVie China, and Bloomberg Industry Research, highlighting the expertise present at the event [4]